-
Reproductive Sciences (Thousand Oaks,... Sep 2021Long non-coding RNAs (lncRNAs) are emerging regulators of cellular pathways, especially in cancer development. Among the lncRNAs, nuclear paraspeckle assembly transcript...
Long non-coding RNAs (lncRNAs) are emerging regulators of cellular pathways, especially in cancer development. Among the lncRNAs, nuclear paraspeckle assembly transcript 1 (NEAT1) forms a scaffold for a nuclear body; the paraspeckle and aberrant expression of NEAT1 have been reported in breast and gynecologic cancers (ovarian, cervical, endometrial, and vulvar). Abundantly expressed NEAT1 in breast and gynecologic cancers generally contribute to tumor development by sponging its corresponding tumor-suppressive microRNAs or interacting with various regulatory proteins. The distinct expression of NEAT1 and its contribution to tumorigenic pathways make it a promising therapeutic target in breast and gynecologic cancers. Herein, we summarize the functions and molecular mechanisms of NEAT1 in human breast, ovarian, cervical, endometrial, and vulvar cancers. Furthermore, we emphasize its critical role in the formation of paraspeckle development and its functions. Conclusively, NEAT1 is a considerable biomarker with a bright prospect and can be therapeutically targeted to manage breast and gynecologic cancers.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Clinical Decision-Making; Female; Gene Expression Regulation, Neoplastic; Genital Neoplasms, Female; Humans; Ovarian Neoplasms; Precision Medicine; Predictive Value of Tests; Prognosis; RNA, Long Noncoding; Signal Transduction; Uterine Neoplasms; Vulvar Neoplasms
PubMed: 33569749
DOI: 10.1007/s43032-021-00481-x -
Expert Review of Molecular Diagnostics Jan 2021Nuclear paraspeckle assembly transcript 1 (NEAT1), a newly found lncRNA, is found abnormally expressed in digestive system tumors. This meta-analysis aims to evaluate... (Meta-Analysis)
Meta-Analysis
OBJECTIVE
Nuclear paraspeckle assembly transcript 1 (NEAT1), a newly found lncRNA, is found abnormally expressed in digestive system tumors. This meta-analysis aims to evaluate the effect of NEAT1 on digestive system tumors.
METHODS
An analysis was conducted to investigate NEAT1 expression in digestive system tumors from the PubMed, Embase, and Web of Science databases. The relationship between NEAT1 expression and patient overall survival (OS) and clinicopathology was evaluated by correlation analysis with the pooled hazard ratio (HR), 95% confidence interval (CI), and odds ratio (OR).
RESULTS
A total of 12 published studies were enrolled in this meta-analysis. The NEAT1 overexpression was significantly associated with poor OS (HR = 1.64, 95% CI:1.41-1.91, < 0.05), lymphatic metastasis (OR = 2.70, 95% CI: 2.02-3.61, < 0.05), distal metastasis (OR = 3.01, 95% CI: 1.97-4.59, < 0.05) and advanced tumor stage (OR = 3.04, 95% CI: 2.32-3.99, < 0.05). However, digestive system tumor patients with high NEAT1 expression was not related to the patients' age (OR = 0.91, 95% CI: 0.65-1.26, = 0.561), gender (OR = 1.04, 95% CI: 0.81-1.33, = 0.761), tumor size (OR = 1.84, 95% CI: 0.88-3.88, = 0.106), and tumor differentiation (OR = 0.86, 95% CI: 0.51-1.44, = 0.570).
CONCLUSION
Collectively, NEAT1 can be used as a potential biomarker to predict the prognosis of patients with digestive system tumors, which is worth verifying in clinical practice.
Topics: Biomarkers; Digestive System Neoplasms; Humans; Prognosis; RNA, Long Noncoding
PubMed: 33550874
DOI: 10.1080/14737159.2021.1874921